Grant: Applied Research Rapid Response to COVID-19
Seneca College of Applied Arts and Technology
$46,841.00
Recombinant protein production in prokaryotic and eukaryotic heterologous hosts for serological assays for_x000d_ COVID-19
FY 2020-21
Summary
Kenota Health (formerly ExVivo Labs), Kitchener, ON, has developed a complete sample-to-result lateral flow
immunoassay testing system for point-of-care medical diagnostics. Kenota's technology fully integrates blood
collection, purification and quantitative analyte analysis with an intuitive easy-to-use interface. Kenota has
designed IgG and IgM antibody tests that can determine COVID-19 exposure in 10 minutes. Kenota plans to
collaborate with Seneca's School of Biological Science and Applied Chemistry to develop processes and
procedures for manufacturing SARS-CoV-2 recombinant proteins. The proposed project will lower the cost of
testing and reduce the risk of delays in availability of tests. These serological assays are critical in determining
the incidence of a pathogen in a population. In future, the ability to identify sensitive and specific SARS-CoV-2
antibodies could support screening of health care workers, minimizing the risk of viral spread to colleagues and
other patients.
Program
Applied Research Rapid Response to COVID-19
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
551372-2020
Name nom
Leaver, Chad
Department département
Head Office
Organization id
1803
Institution établissement
Seneca College of Applied Arts and Technology
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
46841
Program id
COVPJ
Program name en
Applied Research Rapid Response to COVID-19
Program name fr
Recherche appliquée en réponse rapide à la COVID-19
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1597
Committee name en
College and Community Social Innovation Fund
Committee name fr
Programme d'innovation dans les collèges et la communauté Fonds d'innovation sociale
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Recombinant protein production in prokaryotic and eukaryotic heterologous hosts for serological assays for_x000d_
COVID-19
Keyword
NSERC
Application summary
Kenota Health (formerly ExVivo Labs), Kitchener, ON, has developed a complete sample-to-result lateral flow
immunoassay testing system for point-of-care medical diagnostics. Kenota's technology fully integrates blood
collection, purification and quantitative analyte analysis with an intuitive easy-to-use interface. Kenota has
designed IgG and IgM antibody tests that can determine COVID-19 exposure in 10 minutes. Kenota plans to
collaborate with Seneca's School of Biological Science and Applied Chemistry to develop processes and
procedures for manufacturing SARS-CoV-2 recombinant proteins. The proposed project will lower the cost of
testing and reduce the risk of delays in availability of tests. These serological assays are critical in determining
the incidence of a pathogen in a population. In future, the ability to identify sensitive and specific SARS-CoV-2
antibodies could support screening of health care workers, minimizing the risk of viral spread to colleagues and
other patients.
